Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Macitentan and Tadalafil in Newly Diagnosed PAH
NCT02968901Phase 4Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Pulmonary Vascular Resistance at 16 weeks. Started Sep 2015; status: terminated.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02968901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968901.